AR077756A1 - Anticuerpos especificos para bacterias gram-positivas - Google Patents

Anticuerpos especificos para bacterias gram-positivas

Info

Publication number
AR077756A1
AR077756A1 ARP100102587A ARP100102587A AR077756A1 AR 077756 A1 AR077756 A1 AR 077756A1 AR P100102587 A ARP100102587 A AR P100102587A AR P100102587 A ARP100102587 A AR P100102587A AR 077756 A1 AR077756 A1 AR 077756A1
Authority
AR
Argentina
Prior art keywords
gram
positive bacteria
antibody
specific antibodies
aureus
Prior art date
Application number
ARP100102587A
Other languages
English (en)
Original Assignee
Genentech Inc
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Aimm Therapeutics Bv filed Critical Genentech Inc
Publication of AR077756A1 publication Critical patent/AR077756A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Abstract

Compuestos de union capaces de unirse específicamente a bacterias gram-positivas. Los compuestos de union que se proporcionan son totalmente humanos, lo que permite su aplicacion terapéutica en individuos humanos. Uso de los anticuerpos, composicion farmacéutica, método para producir el anticuerpo y secuencias de ácido nucleico. Reivindicacion 14: Un anticuerpo aislado que se une a S. aureus cultivado in vivo. Reivindicacion 33: Un método para aislar bacterias de S. aureus y/o S. epidermidis de una solucion usando un anticuerpo o parte funcional o una cadena de inmunoglobulina o equivalente funcional de ésta de acuerdo con cualquiera de las reivindicaciones 1 - 18.
ARP100102587A 2009-07-15 2010-07-15 Anticuerpos especificos para bacterias gram-positivas AR077756A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
EP09165558 2009-07-15

Publications (1)

Publication Number Publication Date
AR077756A1 true AR077756A1 (es) 2011-09-21

Family

ID=41467048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102587A AR077756A1 (es) 2009-07-15 2010-07-15 Anticuerpos especificos para bacterias gram-positivas

Country Status (24)

Country Link
US (9) US20110020323A1 (es)
EP (1) EP2454284B1 (es)
JP (3) JP6192294B2 (es)
KR (1) KR101832201B1 (es)
CN (2) CN105440133A (es)
AR (1) AR077756A1 (es)
AU (2) AU2010271582B2 (es)
BR (1) BR112012000953A8 (es)
CA (1) CA2768204A1 (es)
DK (1) DK2454284T3 (es)
EA (1) EA031447B1 (es)
ES (1) ES2673323T3 (es)
HK (1) HK1222418A1 (es)
HU (1) HUE038277T2 (es)
IL (3) IL217497A (es)
MX (1) MX350234B (es)
NZ (2) NZ616921A (es)
PL (1) PL2454284T3 (es)
SG (2) SG10201704269RA (es)
SI (1) SI2454284T1 (es)
TR (1) TR201809128T4 (es)
TW (2) TW201610153A (es)
WO (1) WO2011008092A2 (es)
ZA (2) ZA201200363B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
EP2429582A4 (en) 2009-05-13 2013-01-23 Genzyme Corp IMMUNOGLOBULINS ANTI-CD52 HUMAN
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
AR077756A1 (es) 2009-07-15 2011-09-21 Genentech Inc Anticuerpos especificos para bacterias gram-positivas
CN103429615B (zh) * 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
CN102559733A (zh) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
BR112015010125A2 (pt) 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
WO2014142117A1 (ja) * 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
RU2687044C2 (ru) * 2013-05-31 2019-05-06 Дженентек, Инк. Антитела против стеночной тейхоевой кислоты и их конъюгаты
MX369022B (es) * 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3083678B1 (en) 2013-12-17 2019-04-03 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
JP6751393B2 (ja) * 2014-12-03 2020-09-02 ジェネンテック， インコーポレイテッド 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
JP2020522691A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌａｇ−３陽性腫瘍の処置
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (ko) * 2019-11-14 2021-09-13 연세대학교 산학협력단 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
WO2023129822A2 (en) * 2021-12-28 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501418A (ja) 1994-06-07 1998-02-10 ザ・ロックフェラー・ユニバーシティ 黄色ぶどう球菌の表面蛋白
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
EP0807185B9 (en) * 1995-01-30 2002-12-11 Lunamed AG Antitumor preparations containing a lipoteichoic acid from steptococcus
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
AU771426B2 (en) 1998-08-31 2004-03-18 Inhibitex, Inc. Multicomponent vaccines
AU772547B2 (en) 1998-08-31 2004-04-29 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Polypeptides and polynucleotides from coagulase-negative staphylococci
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
AU762978B2 (en) 1998-08-31 2003-07-10 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
AU2002256985B8 (en) 2001-01-26 2008-03-20 Inhibitex, Inc Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004025416A2 (en) 2002-09-13 2004-03-25 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20070026011A1 (en) 2003-05-29 2007-02-01 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
EP1791565B1 (en) * 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2594533A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US8475798B2 (en) 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
AU2007221321B2 (en) 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
KR101508390B1 (ko) * 2006-06-06 2015-04-08 크루셀 홀란드 비.브이. 포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
JP5456658B2 (ja) * 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
CA2683568A1 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CN101302504B (zh) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 一种抗体亲和层析纯化溶葡萄球菌酶的方法
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
US20090162379A1 (en) 2007-10-01 2009-06-25 Magnus Hook Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
US20110150918A1 (en) 2008-01-31 2011-06-23 Timothy Foster Treatment of microbial infections
SI2657253T1 (sl) 2008-01-31 2017-10-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
US8280643B2 (en) 2008-06-30 2012-10-02 The Texas A & M University System Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof
MX2012000044A (es) * 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
AR077756A1 (es) 2009-07-15 2011-09-21 Genentech Inc Anticuerpos especificos para bacterias gram-positivas
WO2011007004A1 (en) 2009-07-16 2011-01-20 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Treatment of infections

Also Published As

Publication number Publication date
SI2454284T1 (en) 2018-07-31
AU2016250398B2 (en) 2018-09-27
EA031447B1 (ru) 2019-01-31
US20130253175A1 (en) 2013-09-26
US20160168232A9 (en) 2016-06-16
AU2016250398A1 (en) 2016-11-17
BR112012000953A2 (pt) 2016-11-22
ZA201400644B (en) 2015-10-28
TW201107470A (en) 2011-03-01
PL2454284T3 (pl) 2018-09-28
BR112012000953A8 (pt) 2017-12-26
WO2011008092A3 (en) 2011-05-26
DK2454284T3 (en) 2018-07-02
HK1222418A1 (zh) 2017-06-30
US20110020323A1 (en) 2011-01-27
SG177653A1 (en) 2012-02-28
TR201809128T4 (tr) 2018-07-23
US20140235828A1 (en) 2014-08-21
MX350234B (es) 2017-08-30
AU2010271582B2 (en) 2016-07-28
IL217497A0 (en) 2012-02-29
IL238074A (en) 2016-06-30
US20120157665A1 (en) 2012-06-21
EA201390967A1 (ru) 2014-01-30
US9688745B2 (en) 2017-06-27
JP2018134089A (ja) 2018-08-30
ES2673323T3 (es) 2018-06-21
US9399673B2 (en) 2016-07-26
JP2016135771A (ja) 2016-07-28
JP6192294B2 (ja) 2017-09-06
JP2012533293A (ja) 2012-12-27
US20160222096A1 (en) 2016-08-04
KR20120065326A (ko) 2012-06-20
AU2010271582A2 (en) 2013-05-16
KR101832201B1 (ko) 2018-02-28
EP2454284A2 (en) 2012-05-23
AU2010271582A1 (en) 2012-03-01
TWI502068B (zh) 2015-10-01
US8617556B2 (en) 2013-12-31
NZ598063A (en) 2014-07-25
US20150376266A1 (en) 2015-12-31
CA2768204A1 (en) 2011-01-20
US9927428B2 (en) 2018-03-27
ZA201200363B (en) 2014-06-25
CN102666583A (zh) 2012-09-12
WO2011008092A4 (en) 2011-07-07
WO2011008092A2 (en) 2011-01-20
US20180292391A1 (en) 2018-10-11
CN105440133A (zh) 2016-03-30
US20170067880A1 (en) 2017-03-09
IL242207A0 (en) 2015-11-30
EP2454284B1 (en) 2018-04-11
US20130261293A1 (en) 2013-10-03
IL217497A (en) 2015-11-30
SG10201704269RA (en) 2017-06-29
CN102666583B (zh) 2015-11-25
NZ616921A (en) 2015-06-26
HUE038277T2 (hu) 2018-10-29
US9090677B2 (en) 2015-07-28
US9458228B2 (en) 2016-10-04
TW201610153A (zh) 2016-03-16
US9266943B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
AR077756A1 (es) Anticuerpos especificos para bacterias gram-positivas
PH12021550083A1 (en) Human anti-tau antibodies
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
AU2018256498A1 (en) Antibodies to amyloid beta
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
CR20170200A (es) Conjugados de anticuerpo-farmaco
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
ECSP12011694A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2-humana
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CY1111518T1 (el) Tgf βητα 1 ειδικα αντισωματα
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
BR112017011478A2 (pt) composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
PA8678401A1 (es) Anticuerpos monoclonales anti-trkb y sus usos
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
AR075604A1 (es) Anticuerpos contra un ligando que induce proliferacion (april)
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer

Legal Events

Date Code Title Description
FB Suspension of granting procedure